Display options
Cite
Menghoum N, Oriot P, Hermans MP. Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period. Diabetes Metab Syndr. 2021;15(6):102275doi: 10.1016/j.dsx.2021.102275.
Menghoum, N., Oriot, P., & Hermans, M. P. (2021). Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period. Diabetes & metabolic syndrome, 15(6), 102275. https://doi.org/10.1016/j.dsx.2021.102275
Menghoum, N, et al. "Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period." Diabetes & metabolic syndrome vol. 15,6 (2021): 102275. doi: https://doi.org/10.1016/j.dsx.2021.102275
Menghoum N, Oriot P, Hermans MP. Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period. Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102275. doi: 10.1016/j.dsx.2021.102275. Epub 2021 Sep 15. PMID: 34562870.
Copy Download .nbib Format: NLM
Share it on

Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102275. doi: 10.1016/j.dsx.2021.102275. Epub 2021 Sep 15.

Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period.

Diabetes & metabolic syndrome

N Menghoum, P Oriot, M P Hermans

Affiliations

  1. Department of Internal Medicine, Mouscron Hospital Center, Avenue de Fécamp 49, 7700, Mouscron, Belgium; Pole of Cardiovascular Research, Institute of Experimental and Clinical Research, Catholic University of Louvain, 1200, Brussels, Belgium.
  2. Department of Internal Medicine, Mouscron Hospital Center, Avenue de Fécamp 49, 7700, Mouscron, Belgium; Department of Diabetology, Mouscron Hospital Centre, Avenue de Fécamp 49, 7700, Mouscron, Belgium. Electronic address: [email protected].
  3. Endocrinology & Nutrition Unit, Cliniques Universitaires St-Luc, and Pole of Cardiovascular Research, Institute of Experimental and Clinical Research, Catholic University of Louvain, Avenue Hippocrate 55, 1200, Brussels, Belgium.

PMID: 34562870 DOI: 10.1016/j.dsx.2021.102275

Abstract

BACKGROUND AND AIMS: To study euglycemic diabetic ketoacidosis (euDKA) outcomes associated with sodium-glucose co-transporter 2 inhibitors (SGLT2is) METHODS: Review of 72 euDKA cases in T2DM between September 2015 and January 2020 (PUBMED).

RESULTS: euDKA could occur at any time during SGLT2is treatment, with nausea, abdominal pain and vomiting as main symptoms. Hyperglycemia did not correlate with pH and β-hydroxybutyrates. Low pH and high β-hydroxybutyrates were significantly associated with euDKA. In biguanides users, acidosis was unrelated to lactic acidosis. euDKA occurred during fasting, surgery, acute infection, insulin deprivation (endogenous or exogenous).

CONCLUSIONS: These data support avoidance of euDKA risk states in SGLT2i users.

Copyright © 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Keywords: Diabetes mellitus; Diabetic ketoacidosis; Euglycemia; SGLT-2 inhibitors; Sodium-glucose transporter 2 inhibitors; Type 2 diabetes mellitus

Conflict of interest statement

Declaration of competing interest The other authors declare that they have no conflict of interest.

Publication Types